-
1 Comment
Jiangsu Bioperfectus Technologies Co., Ltd is currently in a long term downtrend where the price is trading 15.2% below its 200 day moving average.
From a valuation standpoint, the stock is 61.3% cheaper than other stocks from the None sector with a price to sales ratio of 4.8.
Jiangsu Bioperfectus Technologies Co., Ltd's total revenue rose by 550.8% to $639M since the same quarter in the previous year.
Its net income has increased by 599.7% to $238M since the same quarter in the previous year.
Based on the above factors, Jiangsu Bioperfectus Technologies Co., Ltd gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000055B2 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 1.17 |
| Dividend Yield | None |
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. It offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. The company was founded in 2010 and is headquartered in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688399.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
